Research programme: antibacterials - Essential Therapeutics/PanVera
Alternative Names: Antibacterials research programme - Essential Therapeutics/PanVeraLatest Information Update: 05 Oct 2004
At a glance
- Originator Essential Therapeutics [CEASED]
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 05 Oct 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 21 Oct 2003 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 16 Apr 2003 PanVera LLC has been acquired by Invitrogen